Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Prediction of risk of fracture in the tibia due to altered bone mineral density distribution resulting from disuse: A finite element study.
The Mechanisms and Applications of T Cell Vaccination for Autoimmune Diseases: a Comprehensive Review.
Benefits of whole-body vibration with an oscillating platform for people with multiple sclerosis: a systematic review.
A new therapeutic target for the treatment of multiple sclerosis.
Visual resting-state network in relapsing-remitting MS with and without previous optic neuritis.
Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.
Imaging Cortical Damage and Dysfunction in Multiple Sclerosis.
Downbeat nystagmus associated with damage to the medial longitudinal fasciculus of the pons: A vestibular balance control mechanism via the lower brainstem paramedian tract neurons.
Alemtuzumab for relapsing-remitting multiple sclerosis.
Estimating typical multiple sclerosis disability progression speed from clinical observations.
Fatigue is associated with poor sleep in people with multiple sclerosis and cognitive impairment.
Incomplete Septal Cirrhosis After High -Dose Methylprednisolone Therapy And Regression Of Liver Injury.
MRI unsampling using feature-based non-local means approach.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease.
Disease mechanisms in MS: RNA profiling uncovers two distinct subsets of patients with multiple sclerosis.
Triptolide with Potential Medicinal Value for Diseases of the Central Nervous System.
Progesterone alleviates neural behavioral deficits and demyelination with reduced degeneration of oligodendroglial cells in cuprizone-induced mice.
Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.
Age and the role of restricted activities in adjustment to disability related pain.
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.
Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis
Epileptic Seizures in Early-onset Multiple Sclerosis.
Current and emerging therapies in multiple sclerosis: a systematic review.
Pages
« first
‹ previous
…
308
309
310
311
312
313
314
315
316
…
next ›
last »